Auven Therapeutics Announces the Appointment of Beth P. Hecht as a New Partner

October 29, 2012
Auven Therapeutics Announces the Appointment of a New Partner
Read the full press release

ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D

July 17, 2012
ADC Therapeutics (ADCT), the drug development company targeting cancers with antibody-drug conjugate (ADC) “warhead” therapies, today announced the appointment of former Genmab Vice President Dr Patrick van Berkel as Senior Vice President, Research & Development.
Read the full press release

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

July 06, 2012
Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates
Read the full press release

Seattle Genetics announces preclinical results in ADCs from collaboration with Spirogen

April 03, 2012
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR) being held in Chicago, IL.
Read the full press release

Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs

April 03, 2012
Celtic TherapeuticsManagement L.L.L.P. the global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody‐Drug‐Conjugate (“ADC”) products, with the launchof a new Switzerland‐based company.
Read the full press release

Bloomberg Coverage

Bioworld Coverage